Novel Drug Fails for Two Rare Seizure Disorders
(MedPage Today) -- LOS ANGELES -- The novel agent soticlestat flopped in a pair of phase III trials for rare seizure disorders, researchers reported here.
Among Dravet syndrome patients in the SKYLINE trial, the median change from baseline in...
Among Dravet syndrome patients in the SKYLINE trial, the median change from baseline in...